GSK acquires Nuvalent for $10.6 billion
Statements (34)
- Neutral
GSK plc is launching a tender offer to acquire Nuvalent Inc. for $124 per share
- Bullish
GSK plc is likely to see its stock price rise following the acquisition tender offer announcement.
- Bullish
Nuvalent shares are likely to continue rising following GSK's $10.6 billion all-cash buyout offer.
- Bullish
GSK plc entered into a definitive agreement to acquire Boston-based clinical-stage biopharmaceutical specialist
- Bullish
GSK plc is likely to see significant positive market reaction due to its acquisition of Boston-based clinical-stage biopharmaceutical specialist, which could enhance its portfolio and future growth prospects.
- Neutral
GSK acquired Nuvalent for $10.6 billion
- Bullish
GSK announced an agreement to acquire Nuvalent for $10.6 billion
- Neutral
GSK plc agreed to acquire Nuvalent, Inc. for $10.6 billion in cash
- Bullish
GSK is acquiring Nuvalent for $10.6 billion
- Neutral
GSK plc agreed to acquire Nuvalent Inc. for $10.6 billion
- Bullish
GSK is likely to see its stock price rise following its $10.6 billion acquisition of Nuvalent, which will strengthen its cancer portfolio.
- Neutral
GSK struck a $10.6 billion deal to buy Nuvalent
- Neutral
GSK's acquisition of Nuvalent will likely increase GSK's market capitalization due to the substantial cash injection.
- Bullish
GSK is acquiring Nuvalent for $10.6 billion
- Bullish
GSK is likely to see its stock price rise due to its acquisition of Nuvalent for $10.6 billion in a cancer drug drive.
- Bullish
GSK is acquiring Nuvalent for $10.6 billion in a cancer drug initiative
- Bullish
GSK is likely to see increased market confidence and stock price appreciation due to its acquisition of Nuvalent for $10.6 Billion in oncology push.
- Neutral
GSK is acquiring Nuvalent for $10.6 billion in an oncology push
- Bullish
GSK PLC is likely to see its stock price rise following its agreement to acquire Nuvalent for $10.6 billion, which adds advanced lung cancer drugs to its oncology pipeline.
- Bullish
GSK PLC agreed to acquire Nuvalent for $10.6 billion
- Bullish
GSK is likely to see its stock price rise due to its acquisition of Nuvalent for $10.6 billion to expand in cancer drugs.
- Bullish
GSK is acquiring Nuvalent for $10.6 billion to expand its cancer drug business
- Bullish
GSK is likely to see its stock price rise following its acquisition of Nuvalent for $10.6 billion.
- Bullish
GSK is acquiring Nuvalent for $10.6 billion
- Neutral
GSK is in talks to acquire Nuvalent for more than $9 billion
- Bullish
GSK is likely to see its stock price rise as it acquires Nuvalent for more than $9 billion in the biggest deal in over a decade.
- Bullish
GSK is likely to see its stock price rise significantly following its agreement to acquire Nuvalent for more than $9 billion.
- Bullish
GSK is in talks to buy Nuvalent for more than $9 billion
- Bullish
GSK is in talks to buy Nuvalent for more than $9 billion
- Bullish
GSK is likely to see its stock price rise as it announces a $9 billion acquisition of Nuvalent, a cancer biotech company.
- Neutral
GSK has purchased the rights to SiranBio’s metabolic oligonucleotide therapy for up to $1 billion
- Neutral
Bayer is acquiring Perfuse Therapeutics for up to $2.45 billion
- Bullish
GSK plc completed the acquisition of 35Pharma Inc. for $950 million
- Bullish
GSK plc is likely to see positive market reaction due to its completed acquisition of 35Pharma Inc., which expands its drug pipeline.